Don-Hong W. Email & Phone Number

San Francisco, CA, US

San Francisco Bay Area

Develop short-term and long-term strategies to optimize machine learning for improved prediction of TCR and peptide-MHC pairs using AI.

South San Francisco, California, United States

NK + T program optimizing CAR-NK and CAR-T therapy. Designing and optimizing hypoimmune constructs to minimize allogeneic rejection.

South San Francisco, California, United States

Execute IND-enabling studies to screen and identify top CAR-NK hits.

South San Francisco, California

Lead efforts to streamline cell therapy studies by coordinating with cross-functional groups to develop a in vivo screening strategy. Identify target of interest, design genetic constructs with synthetic biologists and execute in vivo studies using syngeneic and xenograft models.

South San Francisco

San Francisco Bay Area

Developed and optimized a multiplex gene expression platform to profile tumor-infiltrating lymphocytes, utilizing FACS and single cell q-PCR technology to identify main population (T cells, B cells, monocytes, macrophages, dendritic cells, and nature killer cells etc) ❒ Utilized Fluidigm Biomark HD platform to interrogate tumor microenvironment in.

Emeryville

Evaluated antibody-cell surface conjugation technology on T cell and developed assay to characterize efficacy in different T cell subtype. ❒ Designed flow cytometry panel to characterize subset of T cells and their activation status.❒ Optimized cell-mediated cytotoxicity assays using flow cytometry and LDH assay. ❒ Led preclinical team and executed IND.

South San Francisco

Contributed to the establishment of Protein Engineering Team and supported company wide discovery research programs. ❒ Developed phage display platform and cloned a series of libraries to enable in-house phage screening.❒ Established standard operating protocols for library quality analysis with next generation sequencing (NGS), phage library screening.

Palo Alto

Analyzed the effect of immune infiltrates in EGFR mutant non-small cell lung cancer (NSCLC) using genetically engineered mouse (GEM) model. ❒ Designed in vivo and ex vivo studies to examine residential lung macrophage as the key source of pathogenic population.❒ Characterized alveolar macrophage during tumor progression with flow cytometry and cytokine.

UC Davis, Dermatology

Identified novel function of PRMT4 methyltransferase and posttranslational regulation on retinoblastoma protein (pRb) during cell cycle. Identified and characterized novel pRb methylation sites critical for cell cycle progression. ❒ Developed tools to characterize methylation site by cloning constitutively methylated-pRB and methylation null-pRB stable.

Sacramento, California Area

Conducted drug discovery research in an interdisciplinary setting involving chemists, pharmacologists, and biologists. Designed a high throughput multiplex library-against-library platform that identifies a broad spectrum of protein inhibitors. Curated a library with a host of small molecules specific to proteomic domains that can be used as inhibitor or.

South San Francisco

Designed and conducted phage display panning and identified bispecific antibodies for new drug candidates. Characterized the Fab fragments using ELISA assay, biacore analysis, and completed phage screening milestone ahead of deadline and found 6 potential antibody candidates for further validations.

Doctor Of Philosophy (Ph.D.), Genetics, Drug Discovery, Antibody Discovery, Protein Engineering, Cancer Research

Bachelor Of Science (Bs), Biotechnology

Education record